Eletriptan (trade name Relpax, used in the form of eletriptan hydrobromide) is a second generation triptan drug intended for treatment of migraine headaches. It is used as an abortive medication, blocking a migraine attack which is already in progress.

The global Eletriptan market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Eletriptan volume and value at global level, regional level and company level. From a global perspective, this report represents overall Eletriptan market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Pfizer
Teva
Mylan
Amneal Pharmaceuticals
Apotex
Ajanta Pharma
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
20mg Tablet
40mg Tablet

Segment by Application
Hospital
Drug store